-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
In an expert roundtable, clinicians discuss the risks, benefits, and anticipated real-world usage of lecanemab following US FDA approval.
Source: Neurology AdvisorCategories: Latest Headlines, NeurologyTweet-
After the recent FDA approval of #lecanemab for the treatment of #AD, clinicians discuss the risks and benefits in real-world clinical settings. #NeuroTwitter https://t.co/a9JEk5d94k
-
-
Mashup Score: 1NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals - 1 year(s) ago
NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
Source: www.jwatch.orgCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Lecanemab, the latest drug for early Alzheimer disease, had a modest effect in a randomized trial, but are the findings clinically relevant? https://t.co/Hu6hfN9Hbe #Alzheimers #lecanemab @NEJM https://t.co/UnYeNW7jay
-
-
Mashup Score: 4
The Food and Drug Administration (FDA) on Friday approved lecanemab for the treatment of Alzheimer’s disease. Lecanemab (brand name Leqemb…
Source: alert.psychnews.orgCategories: Latest Headlines, PsychiatryTweet-
The @US_FDA on Friday approved #lecanemab for the treatment of #Alzheimers disease. It's the second monoclonal antibody that targets a biological component of the disease rather than associated symptoms, such as agitation. https://t.co/Koq64fQkWE #PsychTwitter #MentalHealth
-
-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, NeurologyTweet-
Did you see the big news about #lecanemab? The @US_FDA has approved the #Alzheimers drug that has everyone talking: https://t.co/JmUJaMu6S6 #neurotwitter #dementia @AANMember https://t.co/nhVxWEoppm
-
-
Mashup Score: 0FDA’s Lecanemab Approval Will Raise Pricing, Access Challenges, Says Dr Alvaro Pascual-Leone - 1 year(s) ago
The FDA’s approval of lecanemab for Alzheimer disease is very important, but there will remain significant challenges around pricing and access that will need to be addressed to deliver on the promise the therapy actually represents, said Alvaro Pascual-Leone, MD, PhD, of Harvard Medical School.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The #FDAapproval of #lecanemab for #Alzheimer disease is very important, but significant challenges around #pricing and access will need to be addressed to deliver on the promise the therapy represents, said Dr @alvaropleone of @harvardmed. https://t.co/k21gDJNvRb @Harvard https://t.co/zX4EartFcv
-
-
Mashup Score: 5Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, NeurologyTweet-
The @US_FDA has approved the anti-monoclonal antibody medication #lecanemab to treat #Alzheimers: What you should know about it: https://t.co/L99YGpCpex #neurotwitter #BrainHealth #dementia @AANMember https://t.co/C2Hq2hTcvM
-
-
Mashup Score: 2FDA Approves Lecanemab to Treat Early Alzheimer Disease - 1 year(s) ago
The lecanemab decision follows the controversial 2021 approval of aducanumab, which led to tight coverage restrictions for monoclonal antibodies directed against amyloid for the treatment of Alzheimer disease.
Source: AJMCCategories: General Medicine News, Latest HeadlinesTweet-
RT @AJMC_Journal: The #FDA has approved #lecanemab (Leqembi; Eisai) to treat early #Alzheimer disease. https://t.co/TMThFOaMQp https://t.c…
-
-
Mashup Score: 1FDA Approves Lecanemab to Treat Early Alzheimer Disease - 1 year(s) ago
The lecanemab decision follows the controversial 2021 approval of aducanumab, which led to tight coverage restrictions for monoclonal antibodies directed against amyloid for the treatment of Alzheimer disease.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The #FDA has approved #lecanemab (Leqembi; Eisai) to treat early #Alzheimer disease. https://t.co/TMThFOaMQp https://t.co/YGITgEuabr
-
-
Mashup Score: 3Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, NeurologyTweet-
Why clinicians and researchers feel confident that #Alzheimers drug #lecanemab will win @FDA approval, especially after phase 3 trial results: https://t.co/uwYZqy5NjT #neurotwitter @ApostolovaLiana @holtzman4 @ALZ_Rebecca @MemoryAndAging @YaleMed @AANMember https://t.co/eWu9Kq9Y0G
-
#Lecanemab's arrival may increase demand for testing for #Alzheimers biomarkers, but deciding to prescribe the drug won’t be as easy as looking for a positive or negative result: https://t.co/SCyfugJhtX #neurotwitter #dementia @AANMember @SuzanneESchind1 @PennAging @NMNeurology https://t.co/ddsOuiMsSG